Abstract. In the present study, we investigated whether the peripherally acting µ-opioid receptor agonist loperamide would inhibit allodynia in the non-inflamed dermatome of mice with herpetic pain. Subcutaneous (s.c.) injection of loperamide (1 and 3 mg / kg) inhibited allodynia. Local (intraplantar) injection of loperamide (1 and 5 µg / site) also produced an anti-allodynic effect. The peripheral opioid receptor antagonist naloxone methiodide (0.1 mg / kg, s.c.) and the µ-opioid receptor-selective antagonist β-funaltrexamine (40 nmol / site, intraplantar and 20 mg / kg, s.c.) antagonized the anti-allodynic effects of systemic and local loperamide. Local injection of loperamide into the contralateral hind paw was without effect, suggesting that the effect is mediated through local action, not systemic action. Acute and subacute tolerance did not develop to the anti-allodynic effect of loperamide. In addition, there were no cross-tolerance between local opioids (morphine and loperamide) and systemic morphine. These results suggest that stimulation of peripheral µ-opioid receptors suppresses herpetic allodynia without tolerance development. The non-narcotic µ-opioid receptor agonist loperamide may relieve acute herpetic pain in patients with herpes zoster.
Introduction
Although the analgesic effects of systemic opioids are mainly produced by their action on the central nervous system, peripheral action may also be involved, especially under inflammatory conditions. Experiments and clinical studies have demonstrated that µ-opioid receptor agonists injected locally into the inflamed tissue produce clear analgesic effects (1) . The effect of locally administered opioid may be mediated mainly by peripheral action because systemic administration of similar doses of opioid agonists is not effective (2) and peripherally acting µ-opioid receptor agonist produces analgesic effects (3) . The peripheral analgesic effects of opioids are dose-dependent and are antagonized by naloxone, suggesting opioid receptor-mediated action (2, 4) . µ-Opioid receptors are present on cutaneous nerve endings of sensory neurons (5) and morphine inhibits the activity of cutaneous nociceptors (6) . Thus, the activation of the µ-opioid receptors may decrease the excitability of nociceptors.
An interesting feature of peripheral opioid analgesia in inflamed tissue is the relative lack of tolerance, which is potentially of great advantage. In a non-inflammatory pain model, tolerance has been observed in peripherally mediated analgesia (7) . On the other hand, a lack of tolerance development was shown after repeated local administration of loperamide, a peripherally acting µ-opioid receptor agonist (3, 8) , in a thermal inflammation model (9) . In the same study, systemically applied morphine produced only partial cross-tolerance with loperamide (9) . Clinical studies have also suggested a lack of tolerance development in peripherally mediated analgesia of morphine (10, 11) .
Herpes zoster characterized by clustered vesicles and severe pain is caused by the reactivation of human herpesvirus 3, varicella-zoster virus, in the sensory ganglion in human subjects (12) . Patients with herpes zoster complain of severe spontaneous pain and allodynia, pain due to a non-noxious stimulus, in the affected (inflamed) and adjacent (non-inflamed) dermatomes (13) . Early treatment with antiherpetic agents, such as acyclovir and vidarabine, shortens the duration of skin lesions and complications related to herpes zoster (14) . However, these medicines do not promptly relieve herpetic pain (15) .
Varicella-zoster virus shows high infectious specificity to humans (16) , and the mode of infection in animals is different from that in humans. However, it has been shown that percutaneous inoculation of mice with human herpesvirus 1, herpes simplex virus type-1 (HSV-1), produces zoster-like skin lesions throughout the inoculated dermatome. The mice show pain-like behaviors from day 5 after inoculation, a day when HSV-1 actively replicates in the dorsal root ganglion and vesicles erupt (17, 18) . Pain may be due to inflammation of the nerve and skin as the virus travels from the ganglion along the sensory nerve into the skin. However, the mice show mechanical allodynia in the adjacent dermatome, in which there are no vesicles (17) . The present study was conducted to determine whether the peripherally-acting non-narcotic opioid loperamide inhibits allodynia in the adjacent dermatome.
Materials and Methods

Animals
Female C57BL/ 6j mice (Japan SLC, Shizuoka) were used; they were six-week-old at the start of experiments. Housing (six per cage) and behavioral experiments were done under controlled temperature (22 ± 1°C) and humidity (55 ± 10%). The observation room was lit from 7:00 AM to 7:00 PM and during the behavioral test. Food and water were freely available. Experiments were conducted with the approval of the Animal Care Committee at University of Toyama. The behavioral pain test was done according to the guidelines for investigations of experimental pain in animals published by the International Association for the Study of Pain (19) .
HSV-1 inoculation
The mice were inoculated with HSV-1 as described previously (17) . Briefly, 10 µl of a suspension of HSV-1 (7401H strain; 1 × 10 6 plaque-forming units) was applied to the scarified skin of the right shin. The contralateral hind paw was without inoculation.
Assessment of responses to mechanical stimulation
Mechanical allodynia of the hind paw was assessed as described (17) from day 6 to 8 post-inoculation. After at least 30-min acclimation period, von Frey filament (vFF) with bending force of 1.6 mN was pressed perpendicularly against the plantar skin and was held for 1 -3 s with it slightly buckled; in some experiments, response to vFF with 9.8-mN bending force was also observed. Responses to the stimulus were ranked as follows: 0, no response; 1, lifting of the hind paw; 2, flinching or licking of the hind paw. The stimulation of the same intensity was applied six times to each hind paw at intervals of several seconds and the average served as response score (RS). When naive mice were stimulated with vFF of 1.6-mN bending force, they showed practically no pain-related responses. Therefore, the pain-related response of inoculated mice to it was considered as an allodynia response. Anti-allodynic effect of drugs was calculated as follows:
Anti-allodynic effect (%) = {RS (inoculated side, before drug) − RS (inoculated side, after drug)} / { RS (inoculated side, before drug) − RS (contralateral side, before drug)} × 100
Agents
Morphine hydrochloride (Sankyo, Tokyo) and loperamide hydrochloride (Sigma-Aldrich, St. Louis, MO, USA) were dissolved in physiological saline and 10% dimethyl sulfoxide in physiological saline, respectively. They were administered subcutaneously (s.c.) into the back or intraplantarly (i.pl.). Naloxone methiodide (Sigma-Aldrich) dissolved in physiological saline was administered s.c. at a dose of 0.1 mg / kg. Naloxone methiodide is a peripheral opioid receptor antagonist that crossed the blood-brain barrier only poorly (20) . β-Funaltrexamine (Sigma-Aldrich) dissolved in physiological saline was administered i.pl. or s.c. 24 h before loperamide. β-Funaltrexamine has been demonstrated to selectively block µ-opioid receptors (21). I.pl. and s.c. injections were given in a volume of 20 µl / site and 0.1 ml / 10 g of body weight, respectively. Doses are given as weights of the salt.
Data analyses
The means of data are presented together with S.E.M. Data on the time course of anti-allodynic effects were analyzed with Friedman repeated measures analysis of variance on ranks and then with Dunnett's test. Other data were analyzed with the Mann-Whitney rank sum test or Wilcoxon signed rank test. P<0.05 was considered significant.
Results
Effects of systemic injections of loperamide
HSV-1 inoculation produced allodynia in the sole of the hind paw on the inoculated side, a dermatome adjacent to the affected one. The response to vFF stimuli was caused from day 5 after inoculation and persisted at least until day 8; the response score was 0.09 ± 0.03 and 0.68 ± 0.10 (n = 11) before and seven days after inoculation, respectively. Therefore, medication was done on day 6 -7 after inoculation. Allodynia was not observed in the contralateral hind paw; the response score before and day 7 after inoculation was 0.07 ± 0.02 and 0.02 ± 0.01, respectively (n = 11).
Loperamide at s.c. doses of 1 and 3 mg / kg produced a dose-dependent inhibition of allodynia ( Fig. 1) . The effect peaked 30 -60 min after administration and subsided by 120 min. An s.c. injection of 3 mg / kg of loperamide did not affect the response of naive mice to vFF with a bending force of 9.8 mN; response scores 30 min after injection were 0.72 ± 0.09 and 0.72 ± 0.10 (n = 6) in the vehicle and loperamide groups, respectively.
Effects of local injections of loperamide
Local injections of loperamide (1 and 5 µg / site) into the stimulation site, the plantar region of the hind paw, produced a dose-dependent inhibition of allodynia (Fig. 2) . The effect peaked 15 min after administration and subsided by 60 min. An injection of 5 µg/ site of loperamide into the contralateral hind paw was without effect on allodynia; response scores were 0.73 ± 0.14 and 0.70 ± 0.17 before and 15 min after injection, respectively. In naive mice, an i.pl. injection of 5 µg / site of loperamide did not affect the response to vFF with a bending force of 9.8 mN; response scores 15 min after injection were 0.56 ± 0.12 and 0.58 ± 0.13 (n = 6) in the vehicle and loperamide groups, respectively.
Effect of naloxone methiodide and β-funaltrexamine on anti-allodynic action of loperamide
To investigate the involvement of peripheral µ-opioid receptors, we examined the effect of the peripherallyacting opioid antagonist naloxone methiodide and the µ-opioid receptor-selective antagonist β-funaltrexamine on the loperamide action. The anti-allodynic effect of local injection of loperamide (5 µg / site, i.pl.) was almost completely inhibited by pretreatment with naloxone methiodide (0.1 mg / kg, s.c., −15 min) or β-funaltrexamine (40 nmol, i.pl., −24 h) (Fig. 3A) . The anti-allodynic effect of systemic injection of loperamide (3 mg / kg, s.c.) was also almost completely inhibited by co-administration of naloxone methiodide (0.1 mg / kg, s.c.) or pretreatment with β-funaltrexamine (20 mg / kg, s.c., −24 h) (Fig. 3B) .
Lack of acute and subacute tolerance to peripheral anti-allodynic effect
To examine whether acute tolerance developed to the anti-allodynic effect of peripheral opioid, mice were given twice i.pl. injections of 5 µg / site of loperamide on day 6 after HSV-1 inoculation. The first injection of loperamide inhibited significantly herpetic allodynia and the effect completely subsided 1 h after administration (Fig. 4A) . The second injection of loperamide also produced a significant inhibition of allodynia, the degree of which was similar to that of the first injection (Fig. 4A) . When morphine is injected s.c. into mice with herpetic pain at 12-h intervals, there is a decreased tendency of morphine action and the effects of the third and fourth injections are significantly less than that of the first injection (22) . Therefore, in this series of experiments, loperamide (3 mg / kg) was injected s.c. at 12-h intervals. Tolerance did not develop to the antiallodynic effect of loperamide (Fig. 4B) . Similar results were obtained in the effects of the acute and subacute injections of loperamide on the response to vFF with a bending force of 9.8 mN (data not shown).
Lack of cross-tolerance with systemic morphine
When morphine (5 mg / kg) was injected s.c. at 12-h intervals, the anti-allodynic effect rapidly decreased and the anti-allodynic effect of the fourth administration was significantly weaker than that of the first one (Fig. 5A) . In such mice, the anti-allodynic effect of the fifth s.c. injection of morphine (5 mg / kg) was almost abolished, but the effect of a local (i.pl.) injection of morphine (50 µg / site) was not different between mice given four-times injection of morphine and vehicle (Fig. 5B) . The anti-allodynic effects of s.c loperamide (3 mg / kg) and i.pl. loperamide (5 µg / site) were not affected by four s.c. injections of morphine (Fig. 5B) .
Discussion
The µ-opioid receptor agonist loperamide produced an anti-allodynic effect after s.c. and i.pl. injections in mice with herpetic pain. The i.pl. injection into the contralateral hind paw was without effect and the antiallodynic effects of local and systemic injections of loperamide were antagonized by naloxone methiodide, a peripherally acting opioid antagonist. Thus, the antiallodynic effects are suggested to be mediated by the action on peripheral opioid receptors, probably in the stimulated site. Loperamide is a potent agonist with nanomolar affinity for human µ-opioid receptors, but it also has relatively low affinity for δ-and κ-opioid receptors (3). Loperamide inhibits thermal hyperalgesia but not mechanical allodynia of mice given spinal nerve ligation, and the inhibition of thermal hyperalgesia is antagonized by a δ-opioid, but not µ-opioid, receptor antagonist (23) . In addition, the inhibitory action of loperamide on the colonic mucosa has been claimed to be mediated by δ-and κ-opioid, but not µ-opioid, receptors (24) . In the present study, therefore, we examined the effect of the µ-opioid receptor-selective antagonist β-funaltrexamine on the suppression of herpetic allodynia by loperamide. β-Funaltrexamine almost annulled the loperamide action, suggesting the deep involvement of µ-opioid receptors. The present result is consistent with the suppressive effects of loperamide on the hyperalgesia of mice with bone cancer pain, which is mediated by µ-opioid, but not δ-and κ-opioid, receptors (25) .
An important finding in this study is that loperamide inhibited allodynia in the non-lesioned dermatome adjacent to the affected one. Loperamide at the systemic dose of 1 mg / kg and local dose of 1 µg / site suppressed allodynia, whereas higher doses (systemic dose of 3 mg/ kg and local dose of 5 µg / site) did not affect the pain-related response of the normal hind paw to strong mechanical stimulation. Local and topical administration of opioids produce antinociception in inflamed tissue, and the peripheral opioid analgesia is augmented in inflamed tissues (4, 26) . For example, loperamide at subcutaneous doses of 3 and 10 mg / kg and local doses of 3 -300 µg / site inhibits inflammatory hyperalgesia (3, 20) . Thus, it is interesting that allodynia of the non-lesioned dermatome was suppressed by loperamide at doses effective against inflammatory hyperalgesia. Peripheral inflammation increases µ-opioid receptor and its mRNA in the dorsal root ganglia and axonal transport of µ-opioid receptor along the sciatic nerve (4, 27, 28) , which is thought to be a cause of augmented analgesia of µ-opioid receptor agonists. However, since the increased expression of µ-opioid receptor mRNA is not observed in the dorsal root ganglia of mice with herpetic allodynia (29) , it may not be involved in the anti-allodynic action of loperamide. Since the altered environment in inflamed tissues such as decreased pH may increase opioid agonist efficacy (4, 30) , it is possible that the lesional dermatome affects the adjacent dermatome. This possibility would be tested in the near future.
Tolerance to the analgesic action of opioids is one of major limitations on its clinical use. The antiallodynic effect of morphine rapidly decreased after repeated administration, whereas tolerance was not observed after repeated administration of loperamide. In mice in which tolerance had developed to the antiallodynic effect of systemic morphine, local and systemic administration of loperamide and local administration of morphine produced the anti-allodynic effect without developing tolerance. Thus, it is sug- gested that tolerance does not easily develop to the anti-allodynic effect of peripheral action of opioids. The peripherally restricted effect of opioid avoids central side effects, such as dependence and respiratory depression, which is favorable for clinical use. Additionally, a lack of tolerance development is potentially a great advantage.
Tolerance is prone to develop to the analgesic effect of the central action of opioids (31 -33) . In the central nervous system, endogenous opioid peptides induce tolerance even in a small amount that does not produce analgesia (32, 33) . On the other hand, peripheral opioid analgesia is resistant to the development of tolerance, especially under inflammatory conditions. A lack of tolerance development was shown after repeated local administration of loperamide in the thermal inflammation model (9) . Clinical studies have suggested a lack of tolerance development in the peripherally mediated analgesic action of morphine on inflamed tissues (10, 11) . There is no tolerance to peripheral morphine in spite of the plausible tonic activation of these receptors by immune cell-derived opioids in inflamed tissue (10) . In addition, in a clinical case report, tolerance did not appear to develop after repeated treatment with morphine gel of inflammatory painful skin (11) . Enhanced activities of anti-opioid neurons are suggested to be involved in the development of tolerance to central morphine. There are several antiopioid neuronal systems in the central nervous system, such as cholecystokinin (34) , neuropeptide FF (35) , and nociceptin systems (36) . Since a complicated neuronal network is not present in the peripheral nervous system, peripheral opioid analgesia may be resistant to the development of tolerance.
In non-inflammatory conditions, analgesic tolerance to morphine was reported to develop and not to develop. For example, topical application of morphine inhibits the withdrawal response of the treated region to noxious heat stimulation in mice, and tolerance rapidly develops to the analgesic action after daily application (7) . On the other hand, local injection of morphine inhibits the withdrawal response of mice to bradykinin injected into the same region, and the analgesic action was not suppressed by repeated systemic administration of morphine (37) . It was claimed that the nociceptive fibers could be classified into three types based on the sensitivity to neonatal capsaicin treatment, substance Preceptor antagonist, and glutamate-receptor antagonist (38) . These findings taken together raise the possibility that heat and bradykinin stimulate distinct types of nociceptive fibers, which express different types (prone or hard to develop tolerance) of µ-opioid receptors. In the present study, the anti-allodynic effect of loperamide did not develop tolerance in the non-lesioned dermatome; thus it is speculated that herpetic allodynia is mediated by bradykinin-sensitive or innocuous nerve fibers, which express µ-opioid receptor different from those expressed on heat-sensitive fibers. At least 15 different µ-opioid receptor splice variants have been identified (39) . Antisense manipulation suggests that different µ-opioid receptor splice variants are involved in spinal and supraspinal morphine analgesia (40) . It is interesting to investigate whether different primary afferents express separate splice variants of µ-opioid receptor.
In conclusion, the present study demonstrates that the peripherally-acting non-narcotic opioid loperamide inhibits herpetic allodynia of the dermatome adjacent to the affected one. The anti-allodynic action is suggested to be without acute tolerance and cross-tolerance to systemic morphine.
